S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NYSE:PKI

PerkinElmer - PKI Stock Forecast, Price & News

$127.58
+2.48 (+1.98%)
(As of 03/24/2023 05:19 PM ET)
Add
Compare
Today's Range
$123.08
▼
$127.87
50-Day Range
$120.16
▼
$144.38
52-Week Range
$113.46
▼
$181.65
Volume
791,459 shs
Average Volume
893,254 shs
Market Capitalization
$16.13 billion
P/E Ratio
27.86
Dividend Yield
0.22%
Price Target
$166.30

PerkinElmer MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
30.3% Upside
$166.30 Price Target
Short Interest
Bearish
2.75% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.36mentions of PerkinElmer in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.33 M Sold Last Quarter
Proj. Earnings Growth
17.79%
From $5.06 to $5.96 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.05 out of 5 stars

Computer And Technology Sector

26th out of 604 stocks

Analytical Instruments Industry

1st out of 28 stocks

See Top Rated MarketRank™ Stocks Here

PKI stock logo

About PerkinElmer (NYSE:PKI) Stock

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

March 21, 2023 | americanbankingnews.com
PerkinElmer, Inc. (NYSE:PKI) Receives Average Recommendation of "Hold" from Analysts
March 16, 2023 | americanbankingnews.com
PerkinElmer (NYSE:PKI) Coverage Initiated by Analysts at StockNews.com
March 24, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
March 13, 2023 | finance.yahoo.com
PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses
March 13, 2023 | finance.yahoo.com
Parkland Corporation Announces First Quarter 2023 Dividend
March 11, 2023 | finance.yahoo.com
Declining Stock and Decent Financials: Is The Market Wrong About PerkinElmer, Inc. (NYSE:PKI)?
March 9, 2023 | finance.yahoo.com
PerkinElmer to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
February 15, 2023 | finance.yahoo.com
PerkinElmer, Inc. (NYSE:PKI) Q4 2022 Earnings Call Transcript
March 24, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
February 14, 2023 | finance.yahoo.com
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022
January 24, 2023 | marketwatch.com
PerkinElmer Inc. stock falls Tuesday, underperforms market
January 24, 2023 | msn.com
The Latest Analyst Ratings for PerkinElmer
January 9, 2023 | finance.yahoo.com
PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook
December 26, 2022 | finance.yahoo.com
Investing in PerkinElmer (NYSE:PKI) five years ago would have delivered you a 95% gain
December 12, 2022 | finance.yahoo.com
PerkinElmer, Inc. (NYSE:PKI) is a favorite amongst institutional investors who own 82%
December 8, 2022 | finance.yahoo.com
Why Is PerkinElmer (PKI) Up 10.3% Since Last Earnings Report?
November 21, 2022 | finance.yahoo.com
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
November 17, 2022 | finance.yahoo.com
PerkinElmer Third Quarter 2022 Earnings: EPS Misses Expectations
November 16, 2022 | finance.yahoo.com
PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health
November 16, 2022 | seekingalpha.com
Could PerkinElmer Be The Next Danaher?
November 14, 2022 | finance.yahoo.com
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns
November 10, 2022 | finance.yahoo.com
PerkinElmer to Present at 2022 Stifel Healthcare Conference
November 8, 2022 | finance.yahoo.com
PerkinElmer Announces Financial Results for the Third Quarter of 2022
November 8, 2022 | finance.yahoo.com
PerkinElmer (PKI) Q3 Earnings Surpass Estimates
October 19, 2022 | businesswire.com
Medical Device Innovation Consortium (MDIC) Partners with PerkinElmer's Horizon Discovery to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics - Business Wire
October 17, 2022 | finance.yahoo.com
PerkinElmer Sweetens Its Outlook And Shares Surge, But There's Still One Hitch
October 17, 2022 | marketwatch.com
PerkinElmer Sees 3Q Adj Earnings Topping Guidance - MarketWatch
See More Headlines
Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Company Calendar

Ex-Dividend for 2/10 Dividend
1/19/2023
Dividend Payable
2/10/2023
Last Earnings
2/14/2023
Today
3/24/2023
Ex-Dividend for 5/12 Dividend
4/20/2023
Next Earnings (Estimated)
5/02/2023
Dividend Payable
5/12/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Computer and Technology
Current Symbol
NYSE:PKI
CUSIP
71404610
CIK
31791
Web
www.perkinelmer.com
Phone
(781) 663-6900
Fax
781-663-5985
Employees
16,700
Year Founded
1937

Price Target and Rating

Average Stock Price Forecast
$166.30
High Stock Price Forecast
$182.00
Low Stock Price Forecast
$140.00
Forecasted Upside/Downside
+30.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$4.58
Trailing P/E Ratio
27.86
Forward P/E Ratio
25.21
P/E Growth
0.53
Net Income
$569.18 million
Net Margins
14.69%
Pretax Margin
19.68%
Return on Equity
13.94%
Return on Assets
7.05%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
2.13
Quick Ratio
1.87

Sales & Book Value

Annual Sales
$3.31 billion
Price / Sales
4.87
Cash Flow
$11.96 per share
Price / Cash Flow
10.67
Book Value
$58.49 per share
Price / Book
2.18

Miscellaneous

Outstanding Shares
126,410,000
Free Float
125,755,000
Market Cap
$16.13 billion
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • Prahlad Ramadhar Singh
    President, Chief Executive Officer & Director
  • Tajinder S. Vohra
    Senior Vice President-Global Operations
  • Maxwell Krakowiak
    Chief Financial Officer & Senior Vice President
  • Andrew OkunAndrew Okun
    Chief Accounting Officer, Treasurer & VP
  • Bryan A. Kipp
    VP & General Manager-Life Sciences Integration

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PKI Stock - Frequently Asked Questions

Should I buy or sell PerkinElmer stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PKI shares.
View PKI analyst ratings or view top-rated stocks.

What is PerkinElmer's stock price forecast for 2023?

10 brokerages have issued 12-month price objectives for PerkinElmer's shares. Their PKI share price forecasts range from $140.00 to $182.00. On average, they anticipate the company's stock price to reach $166.30 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price.
View analysts price targets for PKI or view top-rated stocks among Wall Street analysts.

How have PKI shares performed in 2023?

PerkinElmer's stock was trading at $140.22 at the beginning of 2023. Since then, PKI stock has decreased by 9.0% and is now trading at $127.58.
View the best growth stocks for 2023 here.

When is PerkinElmer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PKI earnings forecast.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) announced its quarterly earnings results on Tuesday, February, 14th. The medical research company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.66 by $0.04. The medical research company earned $741.20 million during the quarter, compared to the consensus estimate of $1.07 billion. PerkinElmer had a net margin of 14.69% and a trailing twelve-month return on equity of 13.94%. The company's revenue for the quarter was down 27.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.56 EPS.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, January 26th. Stockholders of record on Friday, April 21st will be paid a dividend of $0.07 per share on Friday, May 12th. This represents a $0.28 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date of this dividend is Thursday, April 20th.
Read our dividend analysis for PKI.

What ETFs hold PerkinElmer's stock?

ETFs with the largest weight of PerkinElmer (NYSE:PKI) stock in their portfolio include AXS Cannabis ETF (THCX), First Trust Indxx Medical Devices ETF (MDEV), WisdomTree BioRevolution Fund (WDNA), Franklin Genomic Advancements ETF (HELX), Janus Henderson US Sustainable Equity ETF (SSPX), Invesco S&P 500 Equal Weight Health Care ETF (RYH), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Guru Index ETF (GURU).

Is PerkinElmer a good dividend stock?

PerkinElmer (NYSE:PKI) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.22%. The dividend payout ratio is 6.11%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PKI will have a dividend payout ratio of 4.70% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PKI.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY23 earnings guidance on Tuesday, February, 14th. The company provided earnings per share (EPS) guidance of $5.05 for the period, compared to the consensus EPS estimate of $5.67. The company issued revenue guidance of $2.94 billion, compared to the consensus revenue estimate of $3.12 billion.

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees.

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a number of institutional and retail investors. Top institutional investors include Moneta Group Investment Advisors LLC (9.41%), Select Equity Group L.P. (7.75%), T. Rowe Price Investment Management Inc. (7.45%), Geode Capital Management LLC (2.01%), Price T Rowe Associates Inc. MD (1.75%) and Alliancebernstein L.P. (1.12%). Insiders that own company stock include Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Peter Barrett, Prahlad R Singh, Sylvie Gregoire and Tajinder S Vohra.
View institutional ownership trends.

How do I buy shares of PerkinElmer?

Shares of PKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $127.58.

How much money does PerkinElmer make?

PerkinElmer (NYSE:PKI) has a market capitalization of $16.13 billion and generates $3.31 billion in revenue each year. The medical research company earns $569.18 million in net income (profit) each year or $4.58 on an earnings per share basis.

How many employees does PerkinElmer have?

The company employs 16,700 workers across the globe.

Does PerkinElmer have any subsidiaries?
The following companies are subsidiares of PerkinElmer: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.
Read More
How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The medical research company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:PKI) was last updated on 3/24/2023 by MarketBeat.com Staff